Thromboembolism and bleeding in newly diagnosed multiple myeloma: rates, risk profile, and patterns of thromboprophylaxis.

ABSTRACT:

Background

Guidelines suggest pharmacological thromboprophylaxis for patients with multiple myeloma (MM) treated with immunomodulatory drugs due to a high risk of venous thromboembolisms (VTE).

Objectives

To analyze rates of VTE and bleeding, risk profiles, and patterns of thromboprophylaxis in MM patients.

Methods

For this cohort study, all consecutive patients with newly diagnosed MM between January 2012 and January 2022 who received induction treatment at our center were included. Characteristics at time of diagnosis, antimyeloma treatment, thromboprophylaxis, and thrombotic and bleeding events during 2-year follow-up were recorded.

Results

Of 293 patients screened, 208 were included. During follow-up, VTE occurred in 19 (9.1%) patients, any bleeding in 35 (

SUBMITTER: Vospernik L 

PROVIDER: S-EPMC12506484 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature